Study of Blood Biomarker 1,5-Anhydroglucitol to Assess Beta-Cell Function in Obese Children With or Without Type 2 Diabetes

What this Trial Is About

Researchers are studying blood levels of 1,5-anhydroglucitol 1,5-AG in obese children aged 12 to 16, with or without type 2 diabetes, to see how these levels relate to beta-cell mass and glucose metabolism. This study aims to test 1,5-AG as a new marker for beta-cell function in children with obesity. The research builds on findings from mouse models and previous studies linking 1,5-AG to diabetes progression and blood sugar control. The study will measure 1,5-AG blood levels in 50 children during planned oral glucose tolerance tests, first at enrollment and again two years later. These measurements will be compared with markers related to beta-cell function, beta-cell mass, and liver function indicators. The study is observational and involves no treatment interventions. Participants will be evaluated twice over two years, with blood tests and oral glucose tolerance tests to assess beta-cell function and metabolic control. Researchers will correlate 1,5-AG levels with these parameters as the primary outcome. Secondary outcomes include examining 1,5-AG associations with liver function. The study will monitor participants health and metabolic data to better understand beta-cell and liver interactions in obese children.

Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function